ctnm: the income statement

MyFinsight

Contineum Therapeutics, Inc. (CTNM)

For the quarter ending 2025-06-30, CTNM made $2,029K in revenue. -$16,040K in net income. Net profit margin of -790.54%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30	2024-09-30	2024-06-30
Unrealized gain (loss) on marketable securities	-	688	-69
Research and development	-	9,728	7,901
General and administrative	-	3,246	3,043
Us-gaap_operatingexpenses	-	12,974	10,944
Us-gaap_operatingincomeloss	-	-12,974	-10,944
Change in fair value of warrant liability	-	-	-11
Other expense, net	-	-34	-77
Interest income	-	2,741	2,001
Us-gaap_nonoperatingincomeexpense	-	2,707	1,935
Us-gaap_incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest	-	-10,267	-9,009
Net income (loss)	-	-10,267	-9,009
Us-gaap_comprehensiveincomenetoftax	-	-9,579	-9,078
Other segment items	167	-	-
Research and development-Unallocated Internal Costs	3,338	-	-
Research and development-PIPE791	6,178	-	-
Research and development-PIPE307	2,160	-	-
Research and development-Discovery Programs	1,328	-	-
Research and development-CTX343	1,059	-	-
Interest income	2,029	-	-
General and administrative	3,839	-	-
Net loss	-16,040	-9,579	-9,078

Basic eps	-	-0.4	-0.39
Diluted eps	-	-0.4	-0.39
Basic average shares	-	25,730,014	23,355,588
Diluted average shares	-	25,730,014	23,355,588

Unit: Thousand (K) dollars (except for numbers of shares and EPS)